Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Immunomedics and AZ/MedImmune enter trial collaboration

Executive Summary

Immunomedics and AstraZeneca PLC/MedImmune LLC entered a trial collaboration to study the potential combination of Imfinzi (durvalumab) and sacituzumab govitecan as a front-line therapy for triple-negative breast cancer and urothelial cancer.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations

Related Companies

Advertisement
UsernamePublicRestriction

Register